TY  - JOUR
AU  - Antonić, Tamara
AU  - Ardalić, Daniela
AU  - Vladimirov, Sandra
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Mitrović, Marija
AU  - Ivanišević, Jasmina
AU  - Gojković, Tamara
AU  - Munjas, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4957
AB  - A specific feature of dyslipidemia in pregnancy is increased high-density lipoprotein (HDL) cholesterol concentration, which is probably associated with maternal endothelium protection. However, preeclampsia is most often associated with low HDL cholesterol, and the mechanisms behind this change are scarcely explored. We aimed to investigate changes in HDL metabolism in risky pregnancies and those complicated by late-onset preeclampsia. We analyze cholesterol synthesis (cholesterol precursors: desmosterol, 7-dehydrocholesterol, and lathosterol) and absorption markers (phytosterols: campesterol and β-sitosterol) within HDL particles (NCSHDL), the activities of principal modulators of HDL cholesterol’s content, and major HDL functional proteins levels in mid and late pregnancy. On the basis of the pregnancy outcome, participants were classified into the risk group (RG) (70 women) and the preeclampsia group (PG) (20 women). HDL cholesterol was lower in PG in the second trimester compared to RG (p < 0.05) and followed by lower levels of cholesterol absorption markers (p < 0.001 for campesterolHDL and p < 0.05 for β-sitosterolHDL). Lowering of HDL cholesterol between trimesters in RG (p < 0.05) was accompanied by a decrease in HDL phytosterol content (p < 0.001), apolipoprotein A-I (apoA-I) concentration (p < 0.05), and paraoxonase 1 (PON1) (p < 0.001), lecithin–cholesterol acyltransferase (LCAT) (p < 0.05), and cholesterol ester transfer protein (CETP) activities (p < 0.05). These longitudinal changes were absent in PG. Development of late-onset preeclampsia is preceded by the appearance of lower HDL cholesterol and NCSHDL in the second trimester. We propose that reduced capacity for intestinal HDL synthesis, decreased LCAT activity, and impaired capacity for HDL-mediated cholesterol efflux could be the contributing mechanisms resulting in lower HDL cholesterol.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia
VL  - 24
IS  - 14
DO  - 10.3390/ijms241411357
ER  - 

@article{
author = "Antonić, Tamara and Ardalić, Daniela and Vladimirov, Sandra and Zeljković, Aleksandra and Vekić, Jelena and Mitrović, Marija and Ivanišević, Jasmina and Gojković, Tamara and Munjas, Jelena and Spasojević-Kalimanovska, Vesna and Miković, Željko and Stefanović, Aleksandra",
year = "2023",
abstract = "A specific feature of dyslipidemia in pregnancy is increased high-density lipoprotein (HDL) cholesterol concentration, which is probably associated with maternal endothelium protection. However, preeclampsia is most often associated with low HDL cholesterol, and the mechanisms behind this change are scarcely explored. We aimed to investigate changes in HDL metabolism in risky pregnancies and those complicated by late-onset preeclampsia. We analyze cholesterol synthesis (cholesterol precursors: desmosterol, 7-dehydrocholesterol, and lathosterol) and absorption markers (phytosterols: campesterol and β-sitosterol) within HDL particles (NCSHDL), the activities of principal modulators of HDL cholesterol’s content, and major HDL functional proteins levels in mid and late pregnancy. On the basis of the pregnancy outcome, participants were classified into the risk group (RG) (70 women) and the preeclampsia group (PG) (20 women). HDL cholesterol was lower in PG in the second trimester compared to RG (p < 0.05) and followed by lower levels of cholesterol absorption markers (p < 0.001 for campesterolHDL and p < 0.05 for β-sitosterolHDL). Lowering of HDL cholesterol between trimesters in RG (p < 0.05) was accompanied by a decrease in HDL phytosterol content (p < 0.001), apolipoprotein A-I (apoA-I) concentration (p < 0.05), and paraoxonase 1 (PON1) (p < 0.001), lecithin–cholesterol acyltransferase (LCAT) (p < 0.05), and cholesterol ester transfer protein (CETP) activities (p < 0.05). These longitudinal changes were absent in PG. Development of late-onset preeclampsia is preceded by the appearance of lower HDL cholesterol and NCSHDL in the second trimester. We propose that reduced capacity for intestinal HDL synthesis, decreased LCAT activity, and impaired capacity for HDL-mediated cholesterol efflux could be the contributing mechanisms resulting in lower HDL cholesterol.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia",
volume = "24",
number = "14",
doi = "10.3390/ijms241411357"
}

Antonić, T., Ardalić, D., Vladimirov, S., Zeljković, A., Vekić, J., Mitrović, M., Ivanišević, J., Gojković, T., Munjas, J., Spasojević-Kalimanovska, V., Miković, Ž.,& Stefanović, A.. (2023). Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia. in International Journal of Molecular Sciences
MDPI., 24(14).
https://doi.org/10.3390/ijms241411357

Antonić T, Ardalić D, Vladimirov S, Zeljković A, Vekić J, Mitrović M, Ivanišević J, Gojković T, Munjas J, Spasojević-Kalimanovska V, Miković Ž, Stefanović A. Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia. in International Journal of Molecular Sciences. 2023;24(14).
doi:10.3390/ijms241411357 .

Antonić, Tamara, Ardalić, Daniela, Vladimirov, Sandra, Zeljković, Aleksandra, Vekić, Jelena, Mitrović, Marija, Ivanišević, Jasmina, Gojković, Tamara, Munjas, Jelena, Spasojević-Kalimanovska, Vesna, Miković, Željko, Stefanović, Aleksandra, "Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia" in International Journal of Molecular Sciences, 24, no. 14 (2023),
https://doi.org/10.3390/ijms241411357 . .

TY  - JOUR
AU  - Ivanišević, Jasmina
AU  - Ardalić, Daniela
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Antonić, Tamara
AU  - Munjas, Jelena
AU  - Stefanović, Aleksandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4637
AB  - The 1st trimester of pregnancy is accompanied with changes in different biochemical and
hematological parameters. Analyses scheduled to be performed in the 1st trimester are complete
blood count, blood group, Rh factor and the double test. Many experts also suggest the
determination of lipid status parameters as a routine analysis in the early pregnancy. Reliable data
about maternal and fetal health can be obtained by the assessment of the above-mentioned
parameters. They may be helpful in assessing the risk for pregnancy complication development
and/or perinatal adverse outcomes.
AB  - Prvi trimestar trudnoće praćen je promenama različitih biohemijskih i hematoloških
parametara. Analize koje se rade u 1. trimestru su kompletna krvna slika, krvna grupa, Rh faktor
i tzv. „double“ test. Mnogi stručnjaci predlažu određivanje parametara lipidnog statusa kao
rutinsku analizu u ranoj trudnoći. Procenom gore navedenih parametara mogu se dobiti pouzdani
podaci o zdravlju majke i fetusa, a mogu da posluže i za procenu rizika za razvoj komplikacija u
trudnoći i/ili perinatalnih neželjenih ishoda.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Biochemical and hematological parameters in the  1 st  trimester of pregnancy
T1  - Biohemijski i hematološki parametri u prvom  trimestru trudnoće
VL  - 73
IS  - 1
SP  - 62
EP  - 73
DO  - 10.5937/arhfarm73-41999
ER  - 

@article{
author = "Ivanišević, Jasmina and Ardalić, Daniela and Zeljković, Aleksandra and Vekić, Jelena and Gojković, Tamara and Vladimirov, Sandra and Antonić, Tamara and Munjas, Jelena and Stefanović, Aleksandra",
year = "2023",
abstract = "The 1st trimester of pregnancy is accompanied with changes in different biochemical and
hematological parameters. Analyses scheduled to be performed in the 1st trimester are complete
blood count, blood group, Rh factor and the double test. Many experts also suggest the
determination of lipid status parameters as a routine analysis in the early pregnancy. Reliable data
about maternal and fetal health can be obtained by the assessment of the above-mentioned
parameters. They may be helpful in assessing the risk for pregnancy complication development
and/or perinatal adverse outcomes., Prvi trimestar trudnoće praćen je promenama različitih biohemijskih i hematoloških
parametara. Analize koje se rade u 1. trimestru su kompletna krvna slika, krvna grupa, Rh faktor
i tzv. „double“ test. Mnogi stručnjaci predlažu određivanje parametara lipidnog statusa kao
rutinsku analizu u ranoj trudnoći. Procenom gore navedenih parametara mogu se dobiti pouzdani
podaci o zdravlju majke i fetusa, a mogu da posluže i za procenu rizika za razvoj komplikacija u
trudnoći i/ili perinatalnih neželjenih ishoda.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Biochemical and hematological parameters in the  1 st  trimester of pregnancy, Biohemijski i hematološki parametri u prvom  trimestru trudnoće",
volume = "73",
number = "1",
pages = "62-73",
doi = "10.5937/arhfarm73-41999"
}

Ivanišević, J., Ardalić, D., Zeljković, A., Vekić, J., Gojković, T., Vladimirov, S., Antonić, T., Munjas, J.,& Stefanović, A.. (2023). Biochemical and hematological parameters in the  1 st  trimester of pregnancy. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 73(1), 62-73.
https://doi.org/10.5937/arhfarm73-41999

Ivanišević J, Ardalić D, Zeljković A, Vekić J, Gojković T, Vladimirov S, Antonić T, Munjas J, Stefanović A. Biochemical and hematological parameters in the  1 st  trimester of pregnancy. in Arhiv za farmaciju. 2023;73(1):62-73.
doi:10.5937/arhfarm73-41999 .

Ivanišević, Jasmina, Ardalić, Daniela, Zeljković, Aleksandra, Vekić, Jelena, Gojković, Tamara, Vladimirov, Sandra, Antonić, Tamara, Munjas, Jelena, Stefanović, Aleksandra, "Biochemical and hematological parameters in the  1 st  trimester of pregnancy" in Arhiv za farmaciju, 73, no. 1 (2023):62-73,
https://doi.org/10.5937/arhfarm73-41999 . .

TY  - JOUR
AU  - Petković, Aleksa
AU  - Erceg, Sanja
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Vladimirov, Sandra
AU  - Davidović, Aleksandar
AU  - Vukmirović, Luka
AU  - Milanov, Marko
AU  - Cvijanović, Dane
AU  - Mitić, Tijana
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4955
AB  - Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
PB  - MDPI
T2  - Cells
T1  - LncRNAs as Regulators of Atherosclerotic Plaque Stability
VL  - 12
IS  - 14
DO  - 10.3390/cells12141832
ER  - 

@article{
author = "Petković, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninić, Ana and Vladimirov, Sandra and Davidović, Aleksandar and Vukmirović, Luka and Milanov, Marko and Cvijanović, Dane and Mitić, Tijana and Sopić, Miron",
year = "2023",
abstract = "Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.",
publisher = "MDPI",
journal = "Cells",
title = "LncRNAs as Regulators of Atherosclerotic Plaque Stability",
volume = "12",
number = "14",
doi = "10.3390/cells12141832"
}

Petković, A., Erceg, S., Munjas, J., Ninić, A., Vladimirov, S., Davidović, A., Vukmirović, L., Milanov, M., Cvijanović, D., Mitić, T.,& Sopić, M.. (2023). LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells
MDPI., 12(14).
https://doi.org/10.3390/cells12141832

Petković A, Erceg S, Munjas J, Ninić A, Vladimirov S, Davidović A, Vukmirović L, Milanov M, Cvijanović D, Mitić T, Sopić M. LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells. 2023;12(14).
doi:10.3390/cells12141832 .

Petković, Aleksa, Erceg, Sanja, Munjas, Jelena, Ninić, Ana, Vladimirov, Sandra, Davidović, Aleksandar, Vukmirović, Luka, Milanov, Marko, Cvijanović, Dane, Mitić, Tijana, Sopić, Miron, "LncRNAs as Regulators of Atherosclerotic Plaque Stability" in Cells, 12, no. 14 (2023),
https://doi.org/10.3390/cells12141832 . .

TY  - JOUR
AU  - Zeljković, Aleksandra
AU  - Ardalić, Daniela
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Vladimirov, Sandra
AU  - Rizzo, Manfredi
AU  - Gojković, Tamara
AU  - Ivanišević, Jasmina
AU  - Mihajlović, Marija
AU  - Vujčić, Sanja
AU  - Cabunac, Petar
AU  - Spasojević-Kalimanovska, Vesna
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4314
AB  - Metabolic disorders in pregnancy, particularly gestational diabetes mellitus (GDM), are associated with an increased risk for adverse pregnancy outcome and long-term cardiometabolic health of mother and child. This study analyzed changes of serum cholesterol synthesis and absorption markers during the course of high-risk pregnancies, with respect to the development of GDM. Possible associations of maternal lipid biomarkers with neonatal characteristics were also investigated. The study included 63 women with high risk for development of pregnancy complications. Size and proportions of small low-density (LDL) and high-density lipoprotein (HDL) particles were assessed across trimesters (T1–T3), as well as concentrations of cholesterol synthesis (lathosterol, desmosterol) and absorption markers (campesterol, β-sitosterol). During the study, 15 women developed GDM, while 48 had no complications (non-GDM). As compared to the non-GDM group, women with GDM had significantly higher triglycerides in each trimester, while having a lower HDL-C level in T3. In addition, they had significantly lower levels of β-sitosterol in T3 (p < 0.05). Cholesterol synthesis markers increased across trimesters in both groups. A decrease in serum β-sitosterol levels during the course of pregnancies affected by GDM was observed. The prevalence of small-sized HDL decreased in non-GDM, while in the GDM group remained unchanged across trimesters. Newborn’s size in the non-GDM group was significantly higher (p < 0.01) and inversely associated with proportions of both small, dense LDL and HDL particles (p < 0.05) in maternal plasma in T1. In conclusion, high-risk pregnancies affected by GDM are characterized by altered cholesterol absorption and HDL maturation. Advanced lipid testing may indicate disturbed lipid homeostasis in GDM.
PB  - MDPI
T2  - Metabolites
T1  - Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome
VL  - 12
IS  - 10
DO  - 10.3390/metabo12100959
ER  - 

@article{
author = "Zeljković, Aleksandra and Ardalić, Daniela and Vekić, Jelena and Antonić, Tamara and Vladimirov, Sandra and Rizzo, Manfredi and Gojković, Tamara and Ivanišević, Jasmina and Mihajlović, Marija and Vujčić, Sanja and Cabunac, Petar and Spasojević-Kalimanovska, Vesna and Miković, Željko and Stefanović, Aleksandra",
year = "2022",
abstract = "Metabolic disorders in pregnancy, particularly gestational diabetes mellitus (GDM), are associated with an increased risk for adverse pregnancy outcome and long-term cardiometabolic health of mother and child. This study analyzed changes of serum cholesterol synthesis and absorption markers during the course of high-risk pregnancies, with respect to the development of GDM. Possible associations of maternal lipid biomarkers with neonatal characteristics were also investigated. The study included 63 women with high risk for development of pregnancy complications. Size and proportions of small low-density (LDL) and high-density lipoprotein (HDL) particles were assessed across trimesters (T1–T3), as well as concentrations of cholesterol synthesis (lathosterol, desmosterol) and absorption markers (campesterol, β-sitosterol). During the study, 15 women developed GDM, while 48 had no complications (non-GDM). As compared to the non-GDM group, women with GDM had significantly higher triglycerides in each trimester, while having a lower HDL-C level in T3. In addition, they had significantly lower levels of β-sitosterol in T3 (p < 0.05). Cholesterol synthesis markers increased across trimesters in both groups. A decrease in serum β-sitosterol levels during the course of pregnancies affected by GDM was observed. The prevalence of small-sized HDL decreased in non-GDM, while in the GDM group remained unchanged across trimesters. Newborn’s size in the non-GDM group was significantly higher (p < 0.01) and inversely associated with proportions of both small, dense LDL and HDL particles (p < 0.05) in maternal plasma in T1. In conclusion, high-risk pregnancies affected by GDM are characterized by altered cholesterol absorption and HDL maturation. Advanced lipid testing may indicate disturbed lipid homeostasis in GDM.",
publisher = "MDPI",
journal = "Metabolites",
title = "Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome",
volume = "12",
number = "10",
doi = "10.3390/metabo12100959"
}

Zeljković, A., Ardalić, D., Vekić, J., Antonić, T., Vladimirov, S., Rizzo, M., Gojković, T., Ivanišević, J., Mihajlović, M., Vujčić, S., Cabunac, P., Spasojević-Kalimanovska, V., Miković, Ž.,& Stefanović, A.. (2022). Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome. in Metabolites
MDPI., 12(10).
https://doi.org/10.3390/metabo12100959

Zeljković A, Ardalić D, Vekić J, Antonić T, Vladimirov S, Rizzo M, Gojković T, Ivanišević J, Mihajlović M, Vujčić S, Cabunac P, Spasojević-Kalimanovska V, Miković Ž, Stefanović A. Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome. in Metabolites. 2022;12(10).
doi:10.3390/metabo12100959 .

Zeljković, Aleksandra, Ardalić, Daniela, Vekić, Jelena, Antonić, Tamara, Vladimirov, Sandra, Rizzo, Manfredi, Gojković, Tamara, Ivanišević, Jasmina, Mihajlović, Marija, Vujčić, Sanja, Cabunac, Petar, Spasojević-Kalimanovska, Vesna, Miković, Željko, Stefanović, Aleksandra, "Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome" in Metabolites, 12, no. 10 (2022),
https://doi.org/10.3390/metabo12100959 . .

TY  - CONF
AU  - Antonić, Tamara
AU  - Ardalić, Daniela
AU  - Vladimirov, Sandra
AU  - Marković, Gorica
AU  - Cabunac, Petar
AU  - Mihajlović, Marija
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4644
AB  - Despite significant progress in improving pregnancy outcomes in recent decades,
predicting the risk and treatment of preeclampsia are still major challenges in clinical
practice (1). The aim of this study was to examine non-routine biomarkers in preeclampsia
risk assessment. The study involved 90 women with high-risk pregnancies, 20 of whom
developed preeclampsia by the end of pregnancy. Biochemical parameters were determined
between the 12th and 13 th weeks of gestation. The results of the study showed that women
who later developed preeclampsia had higher concentrations of lathosterol, cholesterol
synthesis marker (p <0.05), inflammatory proteins - monocyte chemoattractant protein-1
(MCP-1), and resistin (p <0.01, both), as well as paraoxonase-1 (PON1) activity (p <0.05).
Binary logistic regression analysis showed that higher concentrations of lathosterol, MCP-1,
resistin, and PON-1 were associated with preeclampsia development. To determine whether
the parameters significant in univariate analysis, are independent predictors of
preeclampsia, we applied multivariate regression analysis. Clinical markers commonly used
in risk assessment (maternal age and body mass index, mean arterial pressure, and uterine
blood flow), lathosterol, MCP-1, resistin, and PON-1 were included in the model. MCP-1 and
resistin stood out as significant independent predictors of preeclampsia. The diagnostic
accuracy of the investigated model was excellent (AUC=0.859). The study results indicated
the importance of a multi-marker approach in risk assessment for preeclampsia
development.
AB  - Uprkos značajnom napretku u poboljšanju ishoda trudnoće poslednjih decenija,
predviđanje rizika i terapija preeklampsije su još uvijek veliki izazovi u kliničkoj praksi (1).
Cilj ove studije je bio ispitivanje biomarkera koji se ne koriste u rutinskoj praksi u proceni
rizika za razvoj preeklampsije. U studiji je učestvovalo 90 žena sa visokorizičnim
trudnoćama, od kojih je 20 razvilo preeklampsiju do kraja trudnoće. Biohemijski parametri
su određivani između 12. i 13. nedelje gestacije. Rezultati studije su pokazali da su žene koje
su razvile preeklampsiju imale više koncentracije latosterola, markera sinteze holesterola (p
<0,05), inflamatornih proteina - monocitnog hemoatraktantnog proteina-1 (MCP-1) i
rezistina (p < 0,01, oba), kao i aktivnost enzima paraoksonaze-1 (PON1) (p <0,05). Binarna
logistička regresiona analiza je pokazala da su više koncentracije latosterola, MCP-1,
rezistina i PON-1 povezane sa razvojem preeklampsije. Da bi se utvrdilo da su parametri koji
su se u univarijantnoj analizi pokazali značajnim, nezavisni prediktori preeklampsije,
primjenili smo multivarijantnu regresionu analizu. U model su ušli klinički parametri koji se
uobičajeno koriste u procjeni rizika (starost i indeks tjelesne mase majke, srednji arterijski
pritisak i protok krvi kroz matericu), latosterol, MCP-1, rezistin i PON-1. MCP-1 i rezistin su
se istakli kao značajni nezavisni prediktori preeklampsije. Pokazana je odlična dijagnostička
tačnost ispitivanog modela (AUC=0,859). Rezultati ove studije su ukazali na značaj
multimarkerskog pristupa u procjeni rizika za razvoj preeklampsije.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Novel biomarkers in preeclampsia risk assessment
T1  - Novi biomarkeri u procjeni rizika za razvoj preeklampsije
VL  - 72
IS  - 4 suplement
SP  - S620
EP  - S621
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4644
ER  - 

@conference{
author = "Antonić, Tamara and Ardalić, Daniela and Vladimirov, Sandra and Marković, Gorica and Cabunac, Petar and Mihajlović, Marija and Miković, Željko and Stefanović, Aleksandra",
year = "2022",
abstract = "Despite significant progress in improving pregnancy outcomes in recent decades,
predicting the risk and treatment of preeclampsia are still major challenges in clinical
practice (1). The aim of this study was to examine non-routine biomarkers in preeclampsia
risk assessment. The study involved 90 women with high-risk pregnancies, 20 of whom
developed preeclampsia by the end of pregnancy. Biochemical parameters were determined
between the 12th and 13 th weeks of gestation. The results of the study showed that women
who later developed preeclampsia had higher concentrations of lathosterol, cholesterol
synthesis marker (p <0.05), inflammatory proteins - monocyte chemoattractant protein-1
(MCP-1), and resistin (p <0.01, both), as well as paraoxonase-1 (PON1) activity (p <0.05).
Binary logistic regression analysis showed that higher concentrations of lathosterol, MCP-1,
resistin, and PON-1 were associated with preeclampsia development. To determine whether
the parameters significant in univariate analysis, are independent predictors of
preeclampsia, we applied multivariate regression analysis. Clinical markers commonly used
in risk assessment (maternal age and body mass index, mean arterial pressure, and uterine
blood flow), lathosterol, MCP-1, resistin, and PON-1 were included in the model. MCP-1 and
resistin stood out as significant independent predictors of preeclampsia. The diagnostic
accuracy of the investigated model was excellent (AUC=0.859). The study results indicated
the importance of a multi-marker approach in risk assessment for preeclampsia
development., Uprkos značajnom napretku u poboljšanju ishoda trudnoće poslednjih decenija,
predviđanje rizika i terapija preeklampsije su još uvijek veliki izazovi u kliničkoj praksi (1).
Cilj ove studije je bio ispitivanje biomarkera koji se ne koriste u rutinskoj praksi u proceni
rizika za razvoj preeklampsije. U studiji je učestvovalo 90 žena sa visokorizičnim
trudnoćama, od kojih je 20 razvilo preeklampsiju do kraja trudnoće. Biohemijski parametri
su određivani između 12. i 13. nedelje gestacije. Rezultati studije su pokazali da su žene koje
su razvile preeklampsiju imale više koncentracije latosterola, markera sinteze holesterola (p
<0,05), inflamatornih proteina - monocitnog hemoatraktantnog proteina-1 (MCP-1) i
rezistina (p < 0,01, oba), kao i aktivnost enzima paraoksonaze-1 (PON1) (p <0,05). Binarna
logistička regresiona analiza je pokazala da su više koncentracije latosterola, MCP-1,
rezistina i PON-1 povezane sa razvojem preeklampsije. Da bi se utvrdilo da su parametri koji
su se u univarijantnoj analizi pokazali značajnim, nezavisni prediktori preeklampsije,
primjenili smo multivarijantnu regresionu analizu. U model su ušli klinički parametri koji se
uobičajeno koriste u procjeni rizika (starost i indeks tjelesne mase majke, srednji arterijski
pritisak i protok krvi kroz matericu), latosterol, MCP-1, rezistin i PON-1. MCP-1 i rezistin su
se istakli kao značajni nezavisni prediktori preeklampsije. Pokazana je odlična dijagnostička
tačnost ispitivanog modela (AUC=0,859). Rezultati ove studije su ukazali na značaj
multimarkerskog pristupa u procjeni rizika za razvoj preeklampsije.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Novel biomarkers in preeclampsia risk assessment, Novi biomarkeri u procjeni rizika za razvoj preeklampsije",
volume = "72",
number = "4 suplement",
pages = "S620-S621",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4644"
}

Antonić, T., Ardalić, D., Vladimirov, S., Marković, G., Cabunac, P., Mihajlović, M., Miković, Ž.,& Stefanović, A.. (2022). Novel biomarkers in preeclampsia risk assessment. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S620-S621.
https://hdl.handle.net/21.15107/rcub_farfar_4644

Antonić T, Ardalić D, Vladimirov S, Marković G, Cabunac P, Mihajlović M, Miković Ž, Stefanović A. Novel biomarkers in preeclampsia risk assessment. in Arhiv za farmaciju. 2022;72(4 suplement):S620-S621.
https://hdl.handle.net/21.15107/rcub_farfar_4644 .

Antonić, Tamara, Ardalić, Daniela, Vladimirov, Sandra, Marković, Gorica, Cabunac, Petar, Mihajlović, Marija, Miković, Željko, Stefanović, Aleksandra, "Novel biomarkers in preeclampsia risk assessment" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S620-S621,
https://hdl.handle.net/21.15107/rcub_farfar_4644 .